4.4 Article

Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Oncology

The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer

Hiromi Watanabe et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)

Article Medicine, General & Internal

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

S. J. Antonia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Review Oncology

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

Vivek Verma et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

Review Biochemistry & Molecular Biology

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Padmanee Sharma et al.

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Julie Brahmer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

H. Borghaei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)